Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Chinese Patent Office
Daiichi Sankyo
Boehringer Ingelheim
Express Scripts
US Department of Justice
US Army
Covington
Julphar
Moodys

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,012,444

« Back to Dashboard

Summary for Patent: 4,012,444
Title: 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
Abstract:Compounds of the formula: ##STR1## and physiologically acceptable acid addition salts thereof, in which R.sup.1 is A. an arylalkyl group, the alkyl portion of which contains from 1 to 6 carbon atoms and the aryl portion of which may be substituted by one or more alkoxy groups or hydroxy groups; or B. an aryloxyalkyl group, the alkyl portion of which contains from 1 to 6 carbon atoms, and the aryloxy portion of which is substituted with one or more alkoxy or hydroxy groups. These compounds have a blocking action on both .alpha.- and .beta.-adrenergic receptors. Processes for the production of these compounds and pharmaceutical compositions containing them are also provided.
Inventor(s): Lunts; Lawrence Henry Charles (London, EN), Collin; David Trevor (London, EN)
Assignee: Allen & Hanburys Limited (London, EN)
Application Number:05/420,547
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 4,012,444

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,012,444

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
34379/69Jul 8, 1969

International Patents Family Members for US Patent 4,012,444

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 280996 ➤ Subscribe
Austria 300763 ➤ Subscribe
Belgium 704037 ➤ Subscribe
Belgium 752892 ➤ Subscribe
Canada 932734 ➤ Subscribe
Canada 983524 ➤ Subscribe
Switzerland 492676 ➤ Subscribe
Switzerland 582647 ➤ Subscribe
Switzerland 583170 ➤ Subscribe
Switzerland 592051 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
McKesson
Novartis
QuintilesIMS
Cipla
Julphar
Moodys
Federal Trade Commission
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot